Julian Harrison is a Director and BTIG Biotechnology Analyst. Prior to BTIG, he was an Equity Research Associate at H.C. Wainwright & Co., covering small- to mid-cap biotechnology and specialty pharmaceutical companies. Previously, Mr. Harrison was a Clinical and Translational Research Assistant at Hospital for Special Surgery. He earned a BS in biology from Cornell University and an MS in health economics from Weill Cornell Medical College.
BackCoverage Area
| Company | Ticker |
|---|---|
| Aclaris Therapeutics | ACRS |
| MoonLake Immunotherapeutics | MLTX |
| CymaBay Therapeutics | CBAY |
| United Therapeutics Corporation | UTHR |
| Matinas BioPharma Holdings, Inc. | MTNB |
| Protagonist Therapeutics, Inc. | PTGX |
| Biora Therapeutics, Inc. | BIOR |
| Rani Therapeutics Holdings, Inc. | RANI |
| Aura Biosciences, Inc. | AURA |
| Aerovate Therapeutics | AVTE |
| Morphic Therapeutic | MORF |
| Liquidia Corporation | LQDA |
| Keros Therapeutics | KROS |
| Outlook Therapeutics | OTLK |
| Viridian Therapeutics | VRDN |